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unitUpper gastrointestinal tract bleeding (UGIB) is a common
sequel of critical illness. Although only 1.5e6.0% of patients
admitted to the intensive care unit (ICU) will have overt
UGIB, most of them will exhibit clinical risk factors, espe-
cially mechanical ventilation for longer than 48 hours and
the presence of a coagulopathy [1,2]. Up to 50% of patients
will die as a result of stress-ulcer bleeding, mostly from
multi-organ failure and deterioration of the underlying
condition [3]. It is widely accepted that stress ulcer pro-
phylaxis (SUP) is indicated for ICU patients at high risk for
bleeding.
Several medications, including proton pump inhibitors
(PPIs), histamine 2 receptor antagonists (H2RAs), and
sucralfate, have been investigated for SUP. In a multi-
center, randomized, blinded, placebo-controlled trial with
1200 patients who required mechanical ventilation, H2RAs
were shown to be superior to sucralfate in reducing clini-
cally important gastrointestinal bleeding [4]. Currently,
only H2RAs and PPIs remain for prophylactic
pharmacotherapy.
To better understand SUP in hospitalized neurosurgical
ICU (NSICU) patients, Lee and colleagues examined the
practice at Far Eastern Memorial Hospital in New Taipei,
Taiwan [5]. Patients who were less than 18 years old, who
had a history of allergy to either esomeprazole or famoti-
dine, no nasogastric tube feeding and gastrointestinal
bleeding on admission were excluded. Sixty patients were
randomly allocated to the esomeprazole group or the
famotidine group. The authors found no statistically sig-
nificant differences in overt UGIB, occult bleeding and
ventilator-associated pneumonia between the esomepra-
zole and famotidine groups. Nevertheless, it is important to
note that only one death (3.3%) occurred within 30 days in
the esomeprazole group while three deaths (10%) occurred
in the famotidine group. Their results are interesting.
However, this study is derived from a single center with a
small sample size, which potentially limits the generaliz-
ability of their results.
A meta-analysis by Barkun et al [6] showed that PPI
prophylaxis significantly decreases rates of clinically sig-
nificant bleeding compared with H2RAs, without affectinghttp://dx.doi.org/10.1016/j.aidm.2014.04.002
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Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.the development of nosocomial pneumonia or mortality
rates.
PPIs and H2RAs present different pharmacological effi-
cacies in preventing stress ulcer bleeding in the ICU. One
study found that the probabilities of stress ulcer bleeding
and ventilator-assisted pneumonia were 1.3% and 10.3%,
respectively, for PPIs versus 6.6% and 10.3%, respectively,
for H2RAs [7]. In one systematic review and meta-analysis
of 1720 patients admitted to ICUs, PPIs were more effec-
tive than H2RAs at reducing overt UGIB (relative risk, 0.35;
95% confidence interval, 0.21e0.59; p < 0.0001; I Z 15%).
However, there were no differences between PPIs and
H2RAs with regard to the risk of nosocomial pneumonia, ICU
mortality, or ICU length of stay [8]. In another survey of 100
physicians (39 attending physicians, 61 residents) regarding
SUP, all residents preferred a PPI for SUP compared with
85% of attending physicians (p < 0.05). However, more
attending physicians than residents agreed that using PPIs
increased the risk of community-acquired pneumonia
(p < 0.05) [9].
In summary, Lee et al’s study highlights the importance
of SUP in the NSICU with reduction in overt UGIB to 3.3% but
without increasing ventilator-associated pneumonia.
Although they did not find any statistically significant dif-
ferences in the preventative effects of PPIs and H2RAs,
recent high-quality meta-analyses still suggest the superi-
ority of PPIs over H2RAs for SUP in at-risk patients [6,8].
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